secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2026-06-16T12:30:30+00:00
Accession:  0001104659-26-074338
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella stockholders approve 750K-share increase to 2024 equity plan; re-elect three directors
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2024 equity incentive plan, increasing authorized shares by 750,000. Votes: 7,692,709 for, 2,475,470 against.
- Re-elected George M. Jenkins, Todd C. Davis, and John Doux, M.D. as Class III directors until 2029 annual meeting.
- Ratified Ernst & Young as independent auditor for 2026 fiscal year: 11,557,687 for, 13,216 against, 6,566 abstain.
- Advisory vote on executive compensation approved (10,008,180 for); board determined future say-on-pay every year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000110465926074338/0001104659-26-074338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000110465926074338/tm2618003d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-074338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer